GlassScriptPhysician profile
Siju T Chacko
NPI 1720017262
$4,766.57
in general payments reported to CMS, 2019-2025
28 companies · $850 in 2025
The $850 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $390 · 2021: $422 · 2022: $674 · 2023: $1,141 · 2024: $825 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,640 · Travel and Lodging: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.01 |
| Travel and Lodging | $174.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,091.47 | 2019-2025 | Dovato, Cabenuva, Rukobia |
| Abbvie INC. | $661.40 | 2019-2025 | Teflaro, Avycaz, Dalvance |
| Paratek Pharmaceuticals, INC. | $605.48 | 2019-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $383.81 | 2019-2023 | Dificid, Zerbaxa |
| Gilead Sciences, INC. | $290.00 | 2019-2025 | |
| Shionogi INC | $246.52 | 2021-2025 | Fetroja |
| Melinta Therapeutics, LLC | $226.13 | 2019-2024 | Rezzayo, Kimyrsa |
| Modernatx, INC. | $174.93 | 2023 | |
| Insmed, INC. | $149.90 | 2020-2025 | Arikayce |
| Ferring Pharmaceuticals INC. | $138.85 | 2024 | Rebyota |
| Smith+Nephew, INC. | $114.98 | 2019 | |
| Napo Pharmaceuticals INC | $110.36 | 2019-2024 | Mytesi |
| Janssen Biotech, INC. | $96.63 | 2020-2022 | |
| La Jolla Pharmaceutical Company | $90.82 | 2023 | Xerava |
| Vyera Pharmaceuticals, LLC | $58.67 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $54.98 | 2025 | Vowst |
| Cumberland Pharmaceuticals, INC. | $49.51 | 2023-2024 | Vibativ |
| Theratechnologies INC. | $35.45 | 2019-2024 | Egrifta, Trogarzo |
| Vanda Pharmaceuticals INC. | $29.88 | 2020 | |
| Mayne Pharma Commercial LLC | $28.89 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $26.63 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $18.96 | 2024 | Ultomiris |
| Horizon Therapeutics Plc | $17.47 | 2020 | |
| Adma Biomanufacturing LLC | $17.14 | 2022 | |
| Philips North America LLC | $16.82 | 2019 | |
| Baxter Healthcare | $15.65 | 2022 | |
| Romark Laboratories, Lc | $15.24 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siju Chacko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.